People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. People receiving weight-loss drug Wegrovy ...

Drug manufacturers are racing to develop an oral version of popular weight loss injectables like Ozempic, and early studies ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Approval announced for injection medication aimed at treatment for adults for obesity and risk of non-fatal myocardial ...

There have been 274 hospitalisations associated with weight-loss injections - far higher than the 68 previously detailed by ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...